Regulatory Affairs
NAFDAC Debunks Claims That Camosunate Has Been Banned in Nigeria
The National Agency for Food and Drug Administration and Control (NAFDAC) has dismissed social media claims that Camosunate, an artesunate-amodiaquine antimalarial medicine, has been banned in Nigeria, urging the public to stop circulating the misinformation and report suspected adverse drug reactions.
The National Agency for Food and Drug Administration and Control (NAFDAC) has debunked claims circulating on social media that Camosunate, an antimalarial medicine containing artesunate and amodiaquine, has been banned in Nigeria.
In a press release dated 21 November 2026, the Agency clarified that it has never banned Camosunate or medicines containing the artesunate-amodiaquine combination.
The clarification follows the circulation of a viral claim alleging that the medicine had been prohibited in the country, prompting concerns among members of the public about its safety and continued use.
NAFDAC urged Nigerians to disregard the claim and avoid sharing unverified information about regulated medicines.
NAFDAC Explains Reported Side Effects of Camosunate
Addressing symptoms mentioned in the circulating claim, the Agency explained that some of them may be associated with known side effects of Camosunate.
These include:
•Nausea and vomiting.
•Diarrhoea.
•Abdominal pain.
•Headache.
•Dizziness.
•Drowsiness.
•Loss of appetite.
However, NAFDAC emphasised that suspected adverse drug reactions should be reported to the Agency for appropriate assessment.
The clarification highlights the importance of distinguishing between recognised medicine side effects and regulatory decisions to ban or withdraw a product.
Public, Healthcare Professionals Urged to Report Adverse Drug Reactions
NAFDAC encouraged members of the public and healthcare professionals to report suspected adverse drug reactions through its NAFDAC Med Safety App, which is available for download on Android and iOS devices.
Reports can also be submitted at the nearest NAFDAC office.
The Agency noted that reporting suspected adverse reactions supports the assessment and monitoring of medicine safety.
NAFDAC Warns Against Circulating Medical Misinformation
The Agency called on Nigerians to stop circulating the false claim and urged those who had already shared it to disseminate the official clarification through the same channels.
According to NAFDAC, this would help counter misinformation and prevent unnecessary public concern.
The clarification was signed by Professor Mojisola Adeyeye, PhD, FAS, Director-General/Chief Executive Officer of NAFDAC.
Implications for Medicine Safety and Public Health
The clarification reinforces the importance of accurate medicine information, particularly when unverified claims about the safety or regulatory status of medicines circulate on social media.
For pharmacists and other healthcare professionals, the development highlights the need to provide patients with evidence-based information about prescribed medicines, explain potential adverse effects and encourage appropriate reporting of suspected reactions.
It also underscores the importance of pharmacovigilance in identifying, assessing and monitoring suspected adverse drug reactions.
Members of the public should rely on official regulatory communications and qualified healthcare professionals when seeking information about the safety and regulatory status of medicines.
NAFDAC's position is clear: Camosunate and medicines containing the artesunate-amodiaquine combination have not been banned by the Agency.